Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vytorin

Roche Basel Switzerland

Lung cancer OK for Tecentriq sets up showdown with Merck and BMS

Broad label will aid Roche’s PD-L1 inhibitor in head-to-head NSCLC market-share battle

- PMLiVE

FDA halts study of Teva and Regeneron’s pain drug fasinumab

Firms to redesign phase III trial excluding patients with advanced osteoarthritis after set back

Roche - Basel

Lucentis claims speedy FDA review for myopia complication

Roche’s drug achieved superior visual acuity gains compared to standard treatment in trials

Bristol-Myers Squibb (BMS) building

Opdivo data confirms poor showing in first-line NSCLC

Lung cancer drug failed to outperform both chemotherapy and Merck & Co’s Keytruda

National Institute for Health and Care Excellence NICE logo

NICE turns down Keytruda for lung cancer in draft guidance

Says long-term benefits for advanced non-small cell lung cancer treatment not proven

Bayer symbol

Bayer and Merck take high-risk heart failure drug into phase III

Embarks on final study of vericiguat despite it not meeting objectives in phase II trial

- PMLiVE

Novartis’ Ilaris wins three new FDA approvals

Immunotherapeutic expands in rare Periodic Fever Syndrome conditions

Sanofi reception

Sanofi eyes March approval for dupilumab in atopic dermatitis

Analysts suggest sales could reach $2.8bn annually if licensed in eczema and asthma

- PMLiVE

Amgen claims first US go-ahead for Humira biosimilar

Amjevita receives FDA approval but faces patent infringement lawsuit from AbbVie

- PMLiVE

Sarepta soars as FDA clears its muscular dystrophy drug

Analysts anticipate blockbuster status for DMD therapy despite efficacy concerns

Sanofi reception

Sanofi fires off another lawsuit against a Lantus biosimilar

Alleges patent infringement by Merck & Co’s biosimilar version filed in the US last month

- PMLiVE

GSK throws gauntlet down to Merck with shingles vaccine data

Shingrix trial reported ninety per cent efficacy in elderly patients who do not respond well to Zostavax

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links